{"filing":{"accession":"0001231919-26-000959","url":"/filing/0001231919-26-000959","form_type":"4","issuer_cik":"0001516551","issuer_name":"Skye Bioscience, Inc.","issuer_name_source":null,"issuer_ticker":"SKYE","issuer_url":"/issuer/0001516551","period_of_report":"2026-08-18","filed_date":"2026-08-20","acceptance_dt":"2026-08-20T17:57:08+00:00","acceptance_label":"2026-08-20 17:57 UTC","ingested_at":"2026-08-21T05:23:33.898496+00:00","ingested_label":"2026-08-21 05:23 UTC","schema_version":null,"source":"Layline","parse_status":"parsed","parse_ok":true,"edgar_url":"https://www.sec.gov/Archives/edgar/data/1516551/0001231919-26-000959-index.htm","day_url":"/filings/2026-08-20"},"owners":[{"owner_cik":"0001219014","owner_name":"ROCKLAGE SCOTT M","url":"/insider/0001219014","anchor":"owner-0001219014","role":"Ten percent owner","officer_title":null,"is_director":false,"is_officer":false,"is_ten_percent":true,"is_other":false,"filing_anchor":"/filing/0001231919-26-000959#owner-0001219014"},{"owner_cik":"0001240357","owner_name":"DIEKMAN JOHN D","url":"/insider/0001240357","anchor":"owner-0001240357","role":"Ten percent owner","officer_title":null,"is_director":false,"is_officer":false,"is_ten_percent":true,"is_other":false,"filing_anchor":"/filing/0001231919-26-000959#owner-0001240357"},{"owner_cik":"0001386509","owner_name":"5AM Ventures II LP","url":"/insider/0001386509","anchor":"owner-0001386509","role":"Ten percent owner","officer_title":null,"is_director":false,"is_officer":false,"is_ten_percent":true,"is_other":false,"filing_anchor":"/filing/0001231919-26-000959#owner-0001386509"},{"owner_cik":"0001390376","owner_name":"5AM CO-INVESTORS II LP","url":"/insider/0001390376","anchor":"owner-0001390376","role":"Ten percent owner","officer_title":null,"is_director":false,"is_officer":false,"is_ten_percent":true,"is_other":false,"filing_anchor":"/filing/0001231919-26-000959#owner-0001390376"},{"owner_cik":"0001555952","owner_name":"5AM Partners II, LLC","url":"/insider/0001555952","anchor":"owner-0001555952","role":"Ten percent owner","officer_title":null,"is_director":false,"is_officer":false,"is_ten_percent":true,"is_other":false,"filing_anchor":"/filing/0001231919-26-000959#owner-0001555952"},{"owner_cik":"0001664281","owner_name":"PARMAR KUSH","url":"/insider/0001664281","anchor":"owner-0001664281","role":"Ten percent owner","officer_title":null,"is_director":false,"is_officer":false,"is_ten_percent":true,"is_other":false,"filing_anchor":"/filing/0001231919-26-000959#owner-0001664281"},{"owner_cik":"0001844435","owner_name":"5AM Ventures VII, L.P.","url":"/insider/0001844435","anchor":"owner-0001844435","role":"Ten percent owner","officer_title":null,"is_director":false,"is_officer":false,"is_ten_percent":true,"is_other":false,"filing_anchor":"/filing/0001231919-26-000959#owner-0001844435"},{"owner_cik":"0001873545","owner_name":"5AM Partners VII, LLC","url":"/insider/0001873545","anchor":"owner-0001873545","role":"Ten percent owner","officer_title":null,"is_director":false,"is_officer":false,"is_ten_percent":true,"is_other":false,"filing_anchor":"/filing/0001231919-26-000959#owner-0001873545"}],"line_owners":[{"owner_name":"5AM CO-INVESTORS II LP; 5AM Partners II, LLC; 5AM Partners VII, LLC; 5AM Ventures II LP; 5AM Ventures VII, L.P.; DIEKMAN JOHN D; PARMAR KUSH; ROCKLAGE SCOTT M","role":"Ten percent owner"}],"transactions":[{"id":9299362,"accession":"0001231919-26-000959","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001231919-26-000959","line_url":"/filing/0001231919-26-000959#line-1","is_derivative":false,"issuer_cik":"0001516551","issuer_name":"Skye Bioscience, Inc.","issuer_ticker":"SKYE","issuer_name_source":null,"issuer_url":"/issuer/0001516551","owner_cik":null,"owner_name":"5AM CO-INVESTORS II LP; 5AM Partners II, LLC; 5AM Partners VII, LLC; 5AM Ventures II LP; 5AM Ventures VII, L.P.; DIEKMAN JOHN D; PARMAR KUSH; ROCKLAGE SCOTT M","owner_display_name":"5AM CO-INVESTORS II LP","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":45090.0,"shares_display":"45,090","price_per_share":0.38,"price_display":"0.38","price_state":"stated","total_value":17134.2,"total_display":"17,134.20","total_whole":"17,134","shares_owned_after":1411974.0,"shares_owned_after_display":"1,411,974","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-08-18","filed_date":"2026-08-20","scope":"global","indirect_nature":"By 5AM Ventures II, L.P.","deemed_execution_date":null,"conversion_or_exercise_price":null,"exercise_date":null,"expiration_date":null,"underlying_security_title":null,"underlying_shares":null,"equity_swap_involved":null,"footnote_ids":null},{"id":9299363,"accession":"0001231919-26-000959","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001231919-26-000959","line_url":"/filing/0001231919-26-000959#line-2","is_derivative":false,"issuer_cik":"0001516551","issuer_name":"Skye Bioscience, Inc.","issuer_ticker":"SKYE","issuer_name_source":null,"issuer_url":"/issuer/0001516551","owner_cik":null,"owner_name":"5AM CO-INVESTORS II LP; 5AM Partners II, LLC; 5AM Partners VII, LLC; 5AM Ventures II LP; 5AM Ventures VII, L.P.; DIEKMAN JOHN D; PARMAR KUSH; ROCKLAGE SCOTT M","owner_display_name":"5AM CO-INVESTORS II LP","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1830.0,"shares_display":"1,830","price_per_share":0.38,"price_display":"0.38","price_state":"stated","total_value":695.4,"total_display":"695.40","total_whole":"695","shares_owned_after":55663.0,"shares_owned_after_display":"55,663","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-08-18","filed_date":"2026-08-20","scope":"global","indirect_nature":"By 5AM Co-Investors II, L.P.","deemed_execution_date":null,"conversion_or_exercise_price":null,"exercise_date":null,"expiration_date":null,"underlying_security_title":null,"underlying_shares":null,"equity_swap_involved":null,"footnote_ids":null},{"id":9299364,"accession":"0001231919-26-000959","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001231919-26-000959","line_url":"/filing/0001231919-26-000959#line-3","is_derivative":false,"issuer_cik":"0001516551","issuer_name":"Skye Bioscience, Inc.","issuer_ticker":"SKYE","issuer_name_source":null,"issuer_url":"/issuer/0001516551","owner_cik":null,"owner_name":"5AM CO-INVESTORS II LP; 5AM Partners II, LLC; 5AM Partners VII, LLC; 5AM Ventures II LP; 5AM Ventures VII, L.P.; DIEKMAN JOHN D; PARMAR KUSH; ROCKLAGE SCOTT M","owner_display_name":"5AM CO-INVESTORS II LP","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":253080.0,"shares_display":"253,080","price_per_share":0.38,"price_display":"0.38","price_state":"stated","total_value":96170.4,"total_display":"96,170.40","total_whole":"96,170","shares_owned_after":7914126.0,"shares_owned_after_display":"7,914,126","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-08-18","filed_date":"2026-08-20","scope":"global","indirect_nature":"By 5AM Ventures VII, L.P.","deemed_execution_date":null,"conversion_or_exercise_price":null,"exercise_date":null,"expiration_date":null,"underlying_security_title":null,"underlying_shares":null,"equity_swap_involved":null,"footnote_ids":null},{"id":9299365,"accession":"0001231919-26-000959","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001231919-26-000959","line_url":"/filing/0001231919-26-000959#line-4","is_derivative":false,"issuer_cik":"0001516551","issuer_name":"Skye Bioscience, Inc.","issuer_ticker":"SKYE","issuer_name_source":null,"issuer_url":"/issuer/0001516551","owner_cik":null,"owner_name":"5AM CO-INVESTORS II LP; 5AM Partners II, LLC; 5AM Partners VII, LLC; 5AM Ventures II LP; 5AM Ventures VII, L.P.; DIEKMAN JOHN D; PARMAR KUSH; ROCKLAGE SCOTT M","owner_display_name":"5AM CO-INVESTORS II LP","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10255.0,"shares_display":"10,255","price_per_share":0.35,"price_display":"0.35","price_state":"stated","total_value":3589.25,"total_display":"3,589.25","total_whole":"3,589","shares_owned_after":1401719.0,"shares_owned_after_display":"1,401,719","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-08-19","filed_date":"2026-08-20","scope":"global","indirect_nature":"By 5AM Ventures II, L.P.","deemed_execution_date":null,"conversion_or_exercise_price":null,"exercise_date":null,"expiration_date":null,"underlying_security_title":null,"underlying_shares":null,"equity_swap_involved":null,"footnote_ids":null},{"id":9299366,"accession":"0001231919-26-000959","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001231919-26-000959","line_url":"/filing/0001231919-26-000959#line-5","is_derivative":false,"issuer_cik":"0001516551","issuer_name":"Skye Bioscience, Inc.","issuer_ticker":"SKYE","issuer_name_source":null,"issuer_url":"/issuer/0001516551","owner_cik":null,"owner_name":"5AM CO-INVESTORS II LP; 5AM Partners II, LLC; 5AM Partners VII, LLC; 5AM Ventures II LP; 5AM Ventures VII, L.P.; DIEKMAN JOHN D; PARMAR KUSH; ROCKLAGE SCOTT M","owner_display_name":"5AM CO-INVESTORS II LP","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":409.0,"shares_display":"409","price_per_share":0.35,"price_display":"0.35","price_state":"stated","total_value":143.15,"total_display":"143.15","total_whole":"143","shares_owned_after":55254.0,"shares_owned_after_display":"55,254","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-08-19","filed_date":"2026-08-20","scope":"global","indirect_nature":"By 5AM Co-Investors II, L.P.","deemed_execution_date":null,"conversion_or_exercise_price":null,"exercise_date":null,"expiration_date":null,"underlying_security_title":null,"underlying_shares":null,"equity_swap_involved":null,"footnote_ids":null},{"id":9299367,"accession":"0001231919-26-000959","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001231919-26-000959","line_url":"/filing/0001231919-26-000959#line-6","is_derivative":false,"issuer_cik":"0001516551","issuer_name":"Skye Bioscience, Inc.","issuer_ticker":"SKYE","issuer_name_source":null,"issuer_url":"/issuer/0001516551","owner_cik":null,"owner_name":"5AM CO-INVESTORS II LP; 5AM Partners II, LLC; 5AM Partners VII, LLC; 5AM Ventures II LP; 5AM Ventures VII, L.P.; DIEKMAN JOHN D; PARMAR KUSH; ROCKLAGE SCOTT M","owner_display_name":"5AM CO-INVESTORS II LP","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":57476.0,"shares_display":"57,476","price_per_share":0.35,"price_display":"0.35","price_state":"stated","total_value":20116.6,"total_display":"20,116.60","total_whole":"20,117","shares_owned_after":7856650.0,"shares_owned_after_display":"7,856,650","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-08-19","filed_date":"2026-08-20","scope":"global","indirect_nature":"By 5AM Ventures VII, L.P.","deemed_execution_date":null,"conversion_or_exercise_price":null,"exercise_date":null,"expiration_date":null,"underlying_security_title":null,"underlying_shares":null,"equity_swap_involved":null,"footnote_ids":null},{"id":9299368,"accession":"0001231919-26-000959","txn_seq":7,"anchor":"line-7","filing_url":"/filing/0001231919-26-000959","line_url":"/filing/0001231919-26-000959#line-7","is_derivative":false,"issuer_cik":"0001516551","issuer_name":"Skye Bioscience, Inc.","issuer_ticker":"SKYE","issuer_name_source":null,"issuer_url":"/issuer/0001516551","owner_cik":null,"owner_name":"5AM CO-INVESTORS II LP; 5AM Partners II, LLC; 5AM Partners VII, LLC; 5AM Ventures II LP; 5AM Ventures VII, L.P.; DIEKMAN JOHN D; PARMAR KUSH; ROCKLAGE SCOTT M","owner_display_name":"5AM CO-INVESTORS II LP","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1159.0,"shares_display":"1,159","price_per_share":0.32,"price_display":"0.32","price_state":"stated","total_value":370.88,"total_display":"370.88","total_whole":"371","shares_owned_after":1400560.0,"shares_owned_after_display":"1,400,560","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-08-20","filed_date":"2026-08-20","scope":"global","indirect_nature":"By 5AM Ventures II, L.P.","deemed_execution_date":null,"conversion_or_exercise_price":null,"exercise_date":null,"expiration_date":null,"underlying_security_title":null,"underlying_shares":null,"equity_swap_involved":null,"footnote_ids":null},{"id":9299369,"accession":"0001231919-26-000959","txn_seq":8,"anchor":"line-8","filing_url":"/filing/0001231919-26-000959","line_url":"/filing/0001231919-26-000959#line-8","is_derivative":false,"issuer_cik":"0001516551","issuer_name":"Skye Bioscience, Inc.","issuer_ticker":"SKYE","issuer_name_source":null,"issuer_url":"/issuer/0001516551","owner_cik":null,"owner_name":"5AM CO-INVESTORS II LP; 5AM Partners II, LLC; 5AM Partners VII, LLC; 5AM Ventures II LP; 5AM Ventures VII, L.P.; DIEKMAN JOHN D; PARMAR KUSH; ROCKLAGE SCOTT M","owner_display_name":"5AM CO-INVESTORS II LP","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":46.0,"shares_display":"46","price_per_share":0.32,"price_display":"0.32","price_state":"stated","total_value":14.72,"total_display":"14.72","total_whole":"15","shares_owned_after":55208.0,"shares_owned_after_display":"55,208","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-08-20","filed_date":"2026-08-20","scope":"global","indirect_nature":"By 5AM Co-Investors II, L.P.","deemed_execution_date":null,"conversion_or_exercise_price":null,"exercise_date":null,"expiration_date":null,"underlying_security_title":null,"underlying_shares":null,"equity_swap_involved":null,"footnote_ids":null},{"id":9299370,"accession":"0001231919-26-000959","txn_seq":9,"anchor":"line-9","filing_url":"/filing/0001231919-26-000959","line_url":"/filing/0001231919-26-000959#line-9","is_derivative":false,"issuer_cik":"0001516551","issuer_name":"Skye Bioscience, Inc.","issuer_ticker":"SKYE","issuer_name_source":null,"issuer_url":"/issuer/0001516551","owner_cik":null,"owner_name":"5AM CO-INVESTORS II LP; 5AM Partners II, LLC; 5AM Partners VII, LLC; 5AM Ventures II LP; 5AM Ventures VII, L.P.; DIEKMAN JOHN D; PARMAR KUSH; ROCKLAGE SCOTT M","owner_display_name":"5AM CO-INVESTORS II LP","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6495.0,"shares_display":"6,495","price_per_share":0.32,"price_display":"0.32","price_state":"stated","total_value":2078.4,"total_display":"2,078.40","total_whole":"2,078","shares_owned_after":7850155.0,"shares_owned_after_display":"7,850,155","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-08-20","filed_date":"2026-08-20","scope":"global","indirect_nature":"By 5AM Ventures VII, L.P.","deemed_execution_date":null,"conversion_or_exercise_price":null,"exercise_date":null,"expiration_date":null,"underlying_security_title":null,"underlying_shares":null,"equity_swap_involved":null,"footnote_ids":null}],"n_transactions":9,"line_constants":{"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true},"provenance":{"source_pass":"Layline","parse_status":"parsed","schema_version":null,"retrieved_at":"2026-08-21T05:23:33.898496+00:00","retrieved_label":"2026-08-21 05:23 UTC","primary_document":"https://www.sec.gov/Archives/edgar/data/1516551/0001231919-26-000959-index.htm","accepted_at":"2026-08-20T17:57:08+00:00","accepted_label":"2026-08-20 17:57 UTC"},"related":[{"accession":"0001598549-26-000005","url":"/filing/0001598549-26-000005","form_type":"4","issuer_cik":"0001516551","issuer_name":"Skye Bioscience, Inc.","issuer_name_source":null,"issuer_ticker":"SKYE","issuer_url":"/issuer/0001516551","period_of_report":"2026-08-18","filed_date":"2026-08-20","acceptance_dt":"2026-08-20T17:59:27+00:00","acceptance_label":"2026-08-20 17:59 UTC","ingested_at":"2026-08-21T05:23:33.898496+00:00","ingested_label":"2026-08-21 05:23 UTC","schema_version":null,"source":"Layline","parse_status":"parsed","parse_ok":true,"edgar_url":"https://www.sec.gov/Archives/edgar/data/1516551/0001598549-26-000005-index.htm","day_url":"/filings/2026-08-20"}],"related_rule":"Other filings held for the same issuer and the same period of report. This is a heuristic match, not an authoritative amendment link: the store holds no 4/A-to-original relation and the catalog does not invent one.","canonical_url":"https://ebomi.com/filing/0001231919-26-000959","retrieved_at":"2026-08-26T17:38:19+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-25","last_ingest":"2026-08-26T05:24:25.741053+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}